Protalix BioTherapeutics, Inc.
AMEX:PLX · New York Stock Exchange American
+$0.09 today
Vol 1.82M · Avg 0.81M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
AMEX:PLX · Revenue to Net Income
Key Ratios
Analysis
$76.4M of revenue converted into $15.3M of net income for the selected period. Gross margin is 63.3% and net margin is 2.0%, showing how much revenue survives after costs and taxes. EPS is $0.18, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $52.7M -1.2% | $53.4M -18.5% | $65.5M +37.5% | $47.6M +24.2% | $38.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $27.5M +13.1% | $24.3M +5.8% | $23.0M +17.3% | $19.6M +19.8% | $16.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $25.2M -13.2% | $29.1M -31.6% | $42.5M +51.6% | $28.0M +27.5% | $22.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 47.8% -6.6pp | 54.5% -10.5pp | 64.9% +6.0pp | 58.9% +1.5pp | 57.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $19.1M +46.9% | $13.0M -24.1% | $17.1M -41.8% | $29.3M -1.3% | $29.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $11.7M -4.2% | $12.2M -18.5% | $15.0M +27.7% | $11.7M -8.0% | $12.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $30.7M +22.1% | $25.2M -21.5% | $32.1M -21.9% | $41.1M -3.3% | $42.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.5M +12.3% | $1.3M +9.5% | $1.2M +9.7% | $1.1M -2.9% | $1.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$3.0M -145.3% | $6.5M -49.6% | $12.9M +220.0% | -$10.8M +43.1% | -$18.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -5.6% -17.8pp | 12.2% -7.5pp | 19.8% +42.4pp | -22.6% +26.8pp | -49.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$5.5M -240.4% | $3.9M -62.6% | $10.5M +180.4% | -$13.0M +36.4% | -$20.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -10.4% -17.8pp | 7.3% -8.6pp | 16.0% +43.3pp | -27.3% +26.0pp | -53.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1M -16.6% | $1.3M +1.0% | $1.3M +12.2% | $1.1M +185.8% | $401.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.2M +12.1% | $1.1M -66.6% | $3.2M +25.7% | $2.5M -66.4% | $7.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$108.0K -145.6% | $237.0K +112.5% | -$1.9M -36.9% | -$1.4M +80.6% | -$7.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$5.6M -235.0% | $4.2M -51.5% | $8.6M +159.5% | -$14.4M +47.8% | -$27.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -10.6% -18.4pp | 7.8% -5.3pp | 13.1% +43.3pp | -30.2% +41.7pp | -71.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $996.0K -18.5% | $1.2M +381.1% | $254.0K -52.1% | $530.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$6.6M -325.2% | $2.9M -64.7% | $8.3M +155.7% | -$14.9M +45.9% | -$27.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -12.5% -18.0pp | 5.5% -7.2pp | 12.7% +44.0pp | -31.3% +40.6pp | -71.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -308.2% | $0 -66.3% | $0 +138.7% | -$0 +50.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -329.8% | $0 -63.4% | $0 +132.3% | -$0 +50.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $78.5M +8.3% | $72.5M +7.4% | $67.5M +39.3% | $48.5M +9.8% | $44.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $78.5M -3.1% | $81.1M -1.7% | $82.4M +70.0% | $48.5M +9.8% | $44.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.18B
Genfit S.A.
GNFT
$445.68M
OmniAb, Inc.
NASDAQ:OABI
$259.02M
Codexis, Inc.
NASDAQ:CDXS
$226.79M
Coherus Oncology, Inc.
NASDAQ:CHRS
$173.21M
Protara Therapeutics, Inc.
NASDAQ:TARA
$154.96M
MediWound Ltd.
NASDAQ:MDWD
$153.38M
Invivyd, Inc.
NASDAQ:IVVD
$128.55M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$98.78M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$72.83M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PLX generate?
Protalix BioTherapeutics, Inc. (PLX) reported $52.74M of revenue in fiscal 2025.
Is PLX profitable?
Protalix BioTherapeutics, Inc. (PLX) reported -$6,604,000.00 of net income, with a net margin of -12.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.